Disease · MONDO_0005260

autism

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. autism. Diseases, record MONDO_0005260. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005260

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: autism; Open Targets
Open Targets ID: MONDO_0005260; Open Targets
Other names: Autism, Early Infantile, Autism, Infantile, Autisms, Autistic Disorder, Autistic disorder of childhood onset (disorder), Disorder, Autistic, Disorders, Autistic, Early Infantile Autism, Infantile Autism, Early, Infantile autism (disorder), Infantile psychosis (disorder), Kanner Syndrome, Kanner's syndrome, Kanners Syndrome, Syndrome, Kanner's, autism (disease), childhood autism, infantile autism; Open Targets
Disease Ontology: DOID:12849; Disease Ontology
MeSH: D001321; MeSH
NCI Thesaurus: C97161; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 50 drugs, from DailyMed, EMA Human Drugs and FDA; Open Targets

Drugs50

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ARIPIPRAZOLE	CHEMBL1112	Small molecule	Approval	DailyMed and FDA	33	10	10	Drugs and targets
RISPERIDONE	CHEMBL85	Small molecule	Approval	DailyMed	129	5	5	Drugs and targets
MELATONIN	CHEMBL45	Small molecule	Approval	EMA Human Drugs	2	1	1	Drugs and targets
OXYTOCIN	CHEMBL395429	Protein	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
FLUOXETINE	CHEMBL41	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
MEMANTINE	CHEMBL807	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
CHYMOTRYPSIN	CHEMBL1201465		Phase 3	ClinicalTrials.gov	3	3	0	Drugs and targets
SECRETIN	CHEMBL6067494	Protein	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
BUMETANIDE	CHEMBL1072	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CYCLOSERINE	CHEMBL771	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 50

See all 50 drugs

Targets111

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HTR2A	5-hydroxytryptamine receptor 2A	8	Serotonin 2a (5-HT2a) receptor agonist; Serotonin 2a (5-HT2a) receptor antagonist	Approval	https://conductscience.org/library/genes/3356	Drugs and targets
DRD2	D(2) dopamine receptor	6	D2-like dopamine receptor antagonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist	Approval	https://conductscience.org/library/genes/1813	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	4	Serotonin 2c (5-HT2c) receptor antagonist	Approval	https://conductscience.org/library/genes/3358	Drugs and targets
GRIN1	Glutamate [NMDA] receptor	3	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/2902	Drugs and targets
GRIN2A	Glutamate [NMDA] receptor	3	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/2903	Drugs and targets
GRIN2B	Glutamate [NMDA] receptor	3	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/2904	Drugs and targets
GRIN2C	Glutamate [NMDA] receptor	3	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/2905	Drugs and targets
GRIN2D	Glutamate [NMDA] receptor	3	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/2906	Drugs and targets
GRIN3A	Glutamate [NMDA] receptor	3	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/116443	Drugs and targets
GRIN3B	Glutamate [NMDA] receptor	3	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/116444	Drugs and targets

1 to 10 of 111

See all 111 targets

Trials78

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01592786	An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)	Phase 2	906	2014-08-07	Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)	MEMANTINE	Its record names the disease	ClinicalTrials.gov
NCT01592773	Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)	Phase 2	747	2015-02-16	Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)	MEMANTINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01592747	Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine	Phase 2	479	2019-04-24	Autistic Disorder, Autism, Asperger's Disorder, Asperger Syndrome, Autism Spectrum Disorders, Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)	MEMANTINE	Its record names the disease	ClinicalTrials.gov
NCT00365859	Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)	Phase 3	330	2010-01-25	Autistic Disorder, Behavioral Symptoms	ARIPIPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00337571	Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)	Phase 3	218	2009-07-23	Behavioral Symptoms, Autistic Disorder	ARIPIPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03204786	Intranasal Vasopressin Treatment in Children With Autism	Phase 2/3	157	2025-09-19	Autism, Autism Spectrum Disorder, ASD	VASOPRESSIN	Its record names the disease	ClinicalTrials.gov
NCT01911442	Lurasidone Pediatric Autism Study	Phase 3	150	2016-02-25	Autism	LURASIDONE	Its record names the disease	ClinicalTrials.gov
NCT00872898	Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism	Phase 2	124	2014-01-14	Autism	MEMANTINE	Its record names the disease	ClinicalTrials.gov
NCT01999894	Open-label Study of Safety and Tolerability of Memantine in Children With Autism	Phase 2	102	2014-03-18	Autism, Pediatric Autism	MEMANTINE	Its record names the disease	ClinicalTrials.gov
NCT00332241	Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).	Phase 3	98	2009-07-23	Autistic Disorder	ARIPIPRAZOLE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 78

See all 78 trials

Comparisons in its trials28

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Memantine to Memantine vs Placebo to Memantine: serious adverse events	0 of 52	1 of 50	102	NCT01999894	Trial comparisons
Aripiprazole vs Placebo: serious adverse events	0 of 47	0 of 50	97	NCT00332241	Trial comparisons
Aripiprazole vs Placebo: serious adverse events	0 of 47	1 of 45	92	NCT01617447	Trial comparisons
Active vs Placebo: serious adverse events	0 of 27	0 of 24	51	NCT01039792	Trial comparisons
Sapropterin vs Placebo: Clinical Global Impression -- Severity (CGI-S) Scale	3 of 23	1 of 23	46	NCT00850070	Trial comparisons
Sapropterin vs Placebo: Clinical Global Impression -- Improvement (CGI-I) Scale	5 of 23	3 of 23	46	NCT00850070	Trial comparisons
Sapropterin vs Placebo: serious adverse events	2 of 23	1 of 23	46	NCT00850070	Trial comparisons
Kuvan Following Active Treatment vs Kuvan Following Placebo: serious adverse events	0 of 20	0 of 21	41	NCT00943579	Trial comparisons
Sulforaphane-rich Broccoli Sprout Extract vs Placebo: serious adverse events	0 of 26	0 of 14	40	NCT01474993	Trial comparisons
Memantine vs Placebo: Treatment Responder	9 of 19	4 of 21	40	NCT01972074	Trial comparisons

1 to 10 of 28

See all 28 comparisons in its trials

Papers from its trials39

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41053929	RESULT	1	PubMed
28696286	RESULT	1	PubMed
28503116	RESULT	1	PubMed
26746121	RESULT	1	PubMed
23782126	RESULT	1	PubMed
23462988	RESULT	1	PubMed
22342106	RESULT	1	PubMed
15602505	RESULT	1	PubMed
15492353	RESULT	1	PubMed
41032298	DERIVED	1	PubMed

1 to 10 of 39

See all 39 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005260

GET https://conductscience.org/api/diseases/v1/MONDO_0005260/drugs?page=2

API reference For AI assistants